Cargando…

Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells

SIMPLE SUMMARY: A lot of interest has been placed into extracellular vesicles as an intercellular communication mechanism with potential clinical application. As these vesicles are found naturally in body fluids such as blood, urine and saliva, it is possible to isolate them from a liquid biopsy to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rincón-Riveros, Andrés, Lopez, Liliana, Villegas, E Victoria, Antonia Rodriguez, Josefa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922229/
https://www.ncbi.nlm.nih.gov/pubmed/33671415
http://dx.doi.org/10.3390/cancers13040847
_version_ 1783658642161008640
author Rincón-Riveros, Andrés
Lopez, Liliana
Villegas, E Victoria
Antonia Rodriguez, Josefa
author_facet Rincón-Riveros, Andrés
Lopez, Liliana
Villegas, E Victoria
Antonia Rodriguez, Josefa
author_sort Rincón-Riveros, Andrés
collection PubMed
description SIMPLE SUMMARY: A lot of interest has been placed into extracellular vesicles as an intercellular communication mechanism with potential clinical application. As these vesicles are found naturally in body fluids such as blood, urine and saliva, it is possible to isolate them from a liquid biopsy to analyze their content, elucidate their interaction with different cell populations (crosstalk) and determine their effect during the development of a particular pathology. Clinical applications of exosomes include the discovery of diagnostic or prognostic biomarkers for cancer and other diseases, and therapeutic approaches such as organ-specific delivery of drugs, among others. Here, we provide a specific review of how extracellular vesicles, such as exosomes, are carriers for biomolecules like immune checkpoint proteins, ligands, receptors and a wide range of RNA species, which can have an impact on cancer development. ABSTRACT: Exosomes are lipid membrane-enclosed vesicles released by all cell types that act at the paracrine or endocrine level to favor cell differentiation, tissue homeostasis, organ remodeling and immune regulation. Their biosynthesis begins with a cell membrane invagination which generates an early endosome that matures to a late endosome. By inward budding of the late endosome membrane, a multivesicular body (MVB) with intraluminal vesicles (ILVs) is generated. The fusion of MVBs with the plasma membrane releases ILVs into the extracellular space as exosomes, ranging in size from 30 to 100 nm in diameter. The bilipid exosome membrane is rich in cholesterol, ceramides and phosphatidylserine and can be loaded with DNA, RNA, microRNAs, proteins and lipids. It has been demonstrated that exosome secretion is a common mechanism used by the tumor to generate an immunosuppressive microenvironment that favors cancer development and progression, allowing tumor escape from immune control. Due to their ability to transport proteins, lipids and nucleic acids from the cell that gave rise to them, exosomes can be used as a source of biomarkers with great potential for clinical applications in diagnostic, prognostic or therapeutic areas. This article will review the latest research findings on exosomes and their contribution to cancer development.
format Online
Article
Text
id pubmed-7922229
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79222292021-03-03 Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells Rincón-Riveros, Andrés Lopez, Liliana Villegas, E Victoria Antonia Rodriguez, Josefa Cancers (Basel) Review SIMPLE SUMMARY: A lot of interest has been placed into extracellular vesicles as an intercellular communication mechanism with potential clinical application. As these vesicles are found naturally in body fluids such as blood, urine and saliva, it is possible to isolate them from a liquid biopsy to analyze their content, elucidate their interaction with different cell populations (crosstalk) and determine their effect during the development of a particular pathology. Clinical applications of exosomes include the discovery of diagnostic or prognostic biomarkers for cancer and other diseases, and therapeutic approaches such as organ-specific delivery of drugs, among others. Here, we provide a specific review of how extracellular vesicles, such as exosomes, are carriers for biomolecules like immune checkpoint proteins, ligands, receptors and a wide range of RNA species, which can have an impact on cancer development. ABSTRACT: Exosomes are lipid membrane-enclosed vesicles released by all cell types that act at the paracrine or endocrine level to favor cell differentiation, tissue homeostasis, organ remodeling and immune regulation. Their biosynthesis begins with a cell membrane invagination which generates an early endosome that matures to a late endosome. By inward budding of the late endosome membrane, a multivesicular body (MVB) with intraluminal vesicles (ILVs) is generated. The fusion of MVBs with the plasma membrane releases ILVs into the extracellular space as exosomes, ranging in size from 30 to 100 nm in diameter. The bilipid exosome membrane is rich in cholesterol, ceramides and phosphatidylserine and can be loaded with DNA, RNA, microRNAs, proteins and lipids. It has been demonstrated that exosome secretion is a common mechanism used by the tumor to generate an immunosuppressive microenvironment that favors cancer development and progression, allowing tumor escape from immune control. Due to their ability to transport proteins, lipids and nucleic acids from the cell that gave rise to them, exosomes can be used as a source of biomarkers with great potential for clinical applications in diagnostic, prognostic or therapeutic areas. This article will review the latest research findings on exosomes and their contribution to cancer development. MDPI 2021-02-17 /pmc/articles/PMC7922229/ /pubmed/33671415 http://dx.doi.org/10.3390/cancers13040847 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rincón-Riveros, Andrés
Lopez, Liliana
Villegas, E Victoria
Antonia Rodriguez, Josefa
Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells
title Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells
title_full Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells
title_fullStr Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells
title_full_unstemmed Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells
title_short Regulation of Antitumor Immune Responses by Exosomes Derived from Tumor and Immune Cells
title_sort regulation of antitumor immune responses by exosomes derived from tumor and immune cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922229/
https://www.ncbi.nlm.nih.gov/pubmed/33671415
http://dx.doi.org/10.3390/cancers13040847
work_keys_str_mv AT rinconriverosandres regulationofantitumorimmuneresponsesbyexosomesderivedfromtumorandimmunecells
AT lopezliliana regulationofantitumorimmuneresponsesbyexosomesderivedfromtumorandimmunecells
AT villegasevictoria regulationofantitumorimmuneresponsesbyexosomesderivedfromtumorandimmunecells
AT antoniarodriguezjosefa regulationofantitumorimmuneresponsesbyexosomesderivedfromtumorandimmunecells